Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Acquires 3,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHIGet Free Report) CEO Amir Heshmatpour acquired 3,000 shares of Neonc Technologies stock in a transaction that occurred on Monday, August 17th. The stock was bought at an average price of $4.37 per share, with a total value of $13,110.00. Following the purchase, the chief executive officer directly owned 3,087,000 shares of the company’s stock, valued at approximately $13,490,190. This trade represents a 0.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Neonc Technologies Stock Up 16.4%

Shares of NTHI stock opened at $4.91 on Tuesday. The stock has a fifty day moving average price of $4.11 and a 200 day moving average price of $6.05. Neonc Technologies Holdings, Inc. has a 1 year low of $3.01 and a 1 year high of $12.99.

Neonc Technologies (NASDAQ:NTHIGet Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Institutional Investors Weigh In On Neonc Technologies

Several institutional investors and hedge funds have recently made changes to their positions in NTHI. Barclays PLC lifted its stake in Neonc Technologies by 5,314.8% in the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after buying an additional 8,982 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Neonc Technologies during the fourth quarter valued at $124,000. OMERS ADMINISTRATION Corp bought a new position in shares of Neonc Technologies during the fourth quarter worth about $126,000. Royal Bank of Canada bought a new position in shares of Neonc Technologies during the first quarter worth about $247,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Neonc Technologies in the 2nd quarter worth about $126,000.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTHI. Wall Street Zen downgraded Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Maxim Group started coverage on Neonc Technologies in a report on Monday, May 18th. They issued a “buy” rating and a $20.00 price target for the company. BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, May 26th. Alliance Global Partners began coverage on shares of Neonc Technologies in a research report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Weiss Ratings lowered shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 24th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $16.00.

View Our Latest Stock Report on NTHI

About Neonc Technologies

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Featured Stories

Insider Buying and Selling by Quarter for Neonc Technologies (NASDAQ:NTHI)

Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.